NERVIANO, Italy & BOSTON--(BUSINESS WIRE)--Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA..

NERVIANO，Italy＆BOSTON-（BUSINESS WIRE）-NERVIANO Medical Sciences S.r.l.，NMS Group S.p.a.（NMS Group）的一部分和NERVIANO Medical Sciences，Inc.，NMS Group的合资子公司，专注于肿瘤药物的发现和早期开发以及意大利最大的肿瘤研发公司，今天宣布，它将在即将举行的AACR-NCI-EORTC分子靶点和癌症治疗国际会议上展示PARP1抑制剂1期研究的初步数据，该会议于10月11日至15日在马萨诸塞州波士顿举行。。

The PARPA Phase 1 studies, PARPA-293-001 and PARPA-293-002 are evaluating NMS-03305293 (NMS-293), an oral, brain-penetrant PARP-1 selective inhibitor as single agent or in combination with temozolomide, in relapsed/refractory selected solid tumor types (PARPA-293-001) or patients with High-grade gliomas (PARPA-293-002, including glioblastoma).

PARPA 1期研究PARPA-293-001和PARPA-293-002正在评估NMS-03305293（NMS-293），一种口服，脑渗透性PARP-1选择性抑制剂作为单药或与替莫唑胺联合用于复发/难治性选择实体瘤类型（PARPA-293-001）或高级别胶质瘤患者（PARPA-293-002，包括胶质母细胞瘤）。

On September 14, 2022, NMS Group entered into a worldwide option agreement with Merck KGaA, Darmstadt, Germany for the development and commercialization of NMS-293..

2022年9月14日，NMS集团与德国达姆施塔特的Merck KGaA签订了全球期权协议，用于NMS-293的开发和商业化。。

Details for the plenary and poster presentations are as follows:

全体会议和海报介绍的详情如下：

Title: Initial Results from 2 Phase I Studies of NMS-03305293, a Selective PARP1 Inhibitor

题目：选择性PARP1抑制剂NMS-03305293的2项I期研究的初步结果

Abstract number: 37568

摘要编号：37568

Poster number: LB_A12

海报编号：LB_A12

Session: Poster Session A

会议：海报会议A

Session date and time: Thursday, October 12 | 12:30 p.m. – 4:00 p.m. ET

会议日期和时间：10月12日星期四|下午12:30-下午4:00

Session location: Level 2, Exhibit Hall D

会议地点：2级，展览厅D

About Nerviano Medical Sciences

关于Nerviano医学科学

Nerviano Medical Sciences S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners..

Nerviano Medical Sciences S.r.l.（NMS Srl）专注于肿瘤学小分子NCE的发现和临床开发。我们对新的作用机制和药物靶点采取创新方法，为癌症患者带来一流和一流的个性化药物。我们目前的流程由NCE组成，NCE均源自我们经过充分验证的激酶平台，该平台涵盖了从早期临床前到临床阶段的项目，并且正在内部和合作伙伴中进行开发。。

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing)..

NMS Srl将生物技术的灵活性与大型制药的质量相结合。在这里，经验丰富的管理团队领导着具有全球视野和广泛的研究，药物发现和临床开发专业知识的高技能专业人员。我们通过NMS集团附属公司Accelera（AdMet）和NerPharMa（制造业）涵盖药物开发的所有其他方面。。

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib..

一个关键优势是我们工业上着名的激酶抑制剂药物发现平台，该平台包括不断发展的化学品系列，具有广泛的知识产权覆盖范围，发现技术和技术，使我们能够在最近批准的创新药物如encorafenib和entrectinib上获得知识产权许可。。

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development..

我们与学术界和临床研究人员以及全球工业合作伙伴合作，将我们的计划从早期发现推进到新药的临床开发。我们寻求进一步的战略合作，以在不同地区开发和商业化我们的产品，以及为临床开发提供有前途的资产许可机会。。

About NMS Group

关于NMS组

NMS Group is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy.

NMS集团是意大利最大的肿瘤研发公司。拥有400多名员工，其中一半以上是受过高等教育的个人，致力于创新研究，开发和制造。NMS激酶抑制剂发现平台以及抗体结合有效载荷平台是该集团创新的推动力，确保全球认可NMS进行个性化治疗。

Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group..

最近，最初由NMS发现的entrectinib是一种靶向激酶抑制剂，用于治疗NTRK1/2/3和ROS1依赖性实体瘤，已获准作为罗氏集团成员的Ignyta获得所有主要市场商业化批准。这进一步证明了NMS集团药物发现平台的竞争力。。

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization..

NMS集团有三个子公司。NMS S.r.l.是一家以FIC/BIC为重点的药物研发公司，拥有十几个抗癌项目的强大渠道，其中三个项目目前正处于早期临床开发阶段。另外两家子公司是Accelera，这是一家临床前CRO公司，以及NerPharMa，它生产支持临床开发和商业化的API和药品。。